The relationship between features of metabolic syndrome and blood adipocytokine concentrations in the morbid obese patients during dynamic weight loss
- 34 Downloads
Bariatric surgery is the most effective method to achieve weight loss in obese subjects.
The aim of this study was to evaluate some adipocytokines and insulin, as well as parameters of metabolic syndrome of the obese patients, for three and six months after vertical banded gastroplasty, in the time of dynamic weight loss.
Seven males and two females aged 28 to 49 years, with long lasting simple obesity and the presence of metabolic syndrome, were studied. After surgical treatment the values of the body mass index, waist circumference, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, triglycerides, and blood concentrations of leptin decreased significantly.
Before surgical operation of all obese patients no statistically significant correlations between studied parameters were noted. Three and six months later a lot of correlations between studied parameters appeared.
In conclusion, (a) vertical-banded gastroplasty is a valuable method in treatment of obese subjects, leading to a significant decrease in body weight and improvement in some parameters of metabolic syndrome in a few months after surgery, (b) adipocytokines, together with an unknown gastric factor, may be key factors in the control of some features of the metabolic syndrome.
KeywordsObesity metabolic syndrome adiponectin leptin resistin
Unable to display preview. Download preview PDF.
- National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)”, JAMA, Vol. 285 (2001), pp. 2486–2497.CrossRefGoogle Scholar
- G.K. Shetty, P.A. Economides, E.S. Horton, Ch.S. Mantzoros and A. Veves: “Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes”, Diabetes Care, Vol. 27, (2004), pp. 2450–2457.PubMedGoogle Scholar
- Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, K. Hotta, I. Shimomura, T. Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. Okubo, K. Matsubara, M. Muraguchi, Y. Ohmoto, T. Funahashi and Y. Matsuzawa: “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity”, Biochem. Biophys. Res. Commun., Vol. 257, (1999), pp. 79–83.PubMedCrossRefGoogle Scholar
- Y. Yamamoto, Y. Hirose, I. Saito, M. Tomita, M. Taniyama, K. Matsubara, Y. Okazaki, T. Ishi, K. Nishikai and T. Saruta: “Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-choesterol, independent of body mass index, in the Japanese population”, Clin. Sci. (Lond.), Vol. 103, (2002), pp. 132–147.Google Scholar
- K.M. Mc Tigue, R. Harris, B. Hemphill, L. Lux, S. Sutton, A.J. Bunton and K.N. Lohr: “Screening and interventions for obesity in adults: summary of the evidence for the US Prevention Task Force”, Ann. Intern. Med., Vol. 139, (2003), pp. 933–949.Google Scholar
- W.J. Pories, M.S. Swanson, K.G. Mac Donald, S.B. Long, P.G. Morris, B.M. Brown, H.A. Barakat, R.A. de Ramon, D. Israel and J.M. Dolezal: “Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus”, Ann. Surg., Vol. 222, (1995), pp. 339–352.PubMedGoogle Scholar
- L. Sjostrom, A-K. Lindroos, M. Peltonen, J. Torgrson, C. Bouchard, B. Carlsoon, S. Dahlgren, B. Larsen, K. Narbro, C.D. Siostrom, M. Sullivan and H. Wedel: “Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery”. N. Engl. J. Med., Vol. 351, (2004), pp. 2683–2693.PubMedCrossRefGoogle Scholar
- N. Kubota, Y. Terauchi, T. Yamauchi, T. Kubota, M. Moroi, J. Matsui, K. Eto, T. Yamashita, J. Kamon, H. Satoh, W. Yano, P. Frogeul, R. Nagai, S. Kimura, T. Kadowaki and T. Noda: “Disruption of adiponectin causes insulin resistance and neointimal formation”, J. Biol. Chem., Vol. 277, (2002), pp. 25863–25866.PubMedCrossRefGoogle Scholar
- T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, K. Kagechika, Y. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel and T. Kadowaki: “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity”, Nat. Med, Vol. 7, (2001), pp. 941–946.PubMedCrossRefGoogle Scholar
- N. Stefan, B. Vozarova, T. Funahashi, Y. Matsuzawa, C. Weyer, S. Lindsay, J.F. Yongren, P.J. Havel, R.E. Pratley, C. Bogardus and P.A. Tataranni: “Plasma adiponectin concentrations in association with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans”, Diabetes, Vol. 51, (2002), pp. 1884–1888.PubMedGoogle Scholar
- T. Yokota, K. Oritani, I. Takahashi, J. Ishikawa, A. Matsuyama, N. Ouchi, S. Kichara, T. Funahashi, A.J. Tenner, Y. Tomiyama and Y. Matsuzawa: “Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages”, Blood, Vol. 96, (2000), pp. 1723–1732.PubMedGoogle Scholar
- N. Ouchi, S. Kichara, Y. Arilsa, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura, S. Yamashita, T. Funahashi and Y. Matsuzawa: “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin”, Circulation, Vol. 100, (1999), pp. 2473–2476.PubMedGoogle Scholar
- N. Satoh, Y. Ogawa, T. Usui, T. Tagami, S. Kono, H. Uesugi, H. Sugiyama, A. Sugawara, K. Yamada, A. Shimatsu, H. Kuzuya and K. Nakao: “Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect”, Diabetes Care, Vol. 26, (2003), pp. 2493–2499.PubMedGoogle Scholar
- I.A. Harsch, C. Koebnick, H. Wallaschofski, S.P. Schahin, E.G. Hahn, J.H. Ficker, T. Lohmann and P.C. Konturek: “Resistin levels in patients with obstructive sleep apnea syndrome-the link to subclinical inflammation?”, Med. Sci. Monitor, Vol. 10, (2004), pp. CR510–515.Google Scholar